Tourmaline Bio, Inc. (NASDAQ:TRML – Get Free Report) Director Parvinder Thiara bought 1,000 shares of Tourmaline Bio stock in a transaction dated Friday, November 17th. The stock was purchased at an average price of $17.31 per share, with a total value of $17,310.00. Following the completion of the purchase, the director now owns 83,782 shares in the company, valued at $1,450,266.42. The purchase was disclosed in a filing with the SEC, which is available at this link.
Tourmaline Bio Price Performance
TRML stock opened at $17.65 on Tuesday. The stock has a market cap of $75.54 million, a price-to-earnings ratio of -1.18 and a beta of 2.26. Tourmaline Bio, Inc. has a 52-week low of $8.90 and a 52-week high of $32.90.
Analyst Upgrades and Downgrades
Several research analysts have issued reports on the company. Guggenheim assumed coverage on Tourmaline Bio in a report on Tuesday, October 31st. They issued a “buy” rating and a $50.00 price target on the stock. Truist Financial initiated coverage on shares of Tourmaline Bio in a research report on Friday. They issued a “buy” rating and a $43.00 price target for the company. Finally, Piper Sandler assumed coverage on shares of Tourmaline Bio in a report on Wednesday, October 25th. They set an “overweight” rating and a $65.00 price objective on the stock.
About Tourmaline Bio
Tourmaline Bio, Inc operates as a clinical biotechnology company that develops medicines for patients with life-altering immune diseases. It develops medicines and therapies for the Atherosclerotic cardiovascular disease (ASCVD) and Thyroid Eye Disease (TED). The company was incorporated in 2021 and is based in New York, New York.
- Five stocks we like better than Tourmaline Bio
- Energy and Oil Stocks Explained
- The most upgraded stocks in November have two things in common
- The “How” and “Why” of Investing in 5G Stocks
- Monday.com rocked earnings like it’s the weekend
- There Are Different Types of Stock To Invest In
- Plan to own one retailer? Make it this one
Receive News & Ratings for Tourmaline Bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tourmaline Bio and related companies with MarketBeat.com's FREE daily email newsletter.